Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 4 2023

Full Issue

So Many Americans Want Obesity Drug Wegovy, Its Maker Is Cutting Supplies

The weight loss drug, currently in the spotlight, comes from Danish maker Novo Nordisk. Nordisk just reported strong first-quarter finances, but said high demand from the U.S. will cause it to reduce supplies of some dose strengths. In related news, employers tackle requests to cover the drug and states combat unauthorized versions.

Danish drug developer Novo Nordisk (NOVOb.CO) on Thursday said it would reduce supply of some dose strengths of its popular Wegovy obesity drug in the United States due to high demand after the firm reported forecast-beating first-quarter results. (5/4)

A growing number of states are threatening to take legal action against pharmacies that make or dispense unauthorized versions of the weight-loss medications Ozempic and Wegovy. At least four states are already curbing the manufacturing of copycat versions over safety concerns and more could soon follow, experts say, as the two medications soar in popularity in the U.S. (Lovelace Jr., 5/3)

Employers are fielding a surge of demand from their workers for obesity care benefits — specifically, for a buzzy class of weight loss drugs — and it's getting pricey. (Reed, 5/4)

Also —

CVS Health cut its 2023 profit expectations after closing acquisitions of primary care operator Oak Street Health and home health company Signify Health earlier than expected, the company announced Wednesday. Transaction and integration costs related to the deals will impact CVS Health's finances in 2023, sooner than anticipated, company executives said during a call with investors. CVS Health had expected to close its $10.6 billion purchase of the Chicago-based Oak Street Health later in the year. (Tepper, 5/3)

Option Care Health on Wednesday announced plans to acquire health and hospice firm Amedisys for $3.6 billion in a deal that reflects companies’ need to build scale as care options increasingly move into the home. The all-stock transaction would create a mammoth provider of post-acute care services, generating approximately $6.2 billion in annual revenue and delivering a variety of in-home services in 46 states and across 674 sites. (Eastabrook, 5/3)

Centene will sell artificial intelligence tool Apixio to investment firm New Mountain Capital as the insurer continues to divest assets outside of its core health insurance business, the company announced Wednesday. Centene and New Mountain Capital did not disclose a purchase price or a timeline for closing the deal, which is subject to regulatory approval. (Tepper, 5/3)

Each year, Modern Healthcare’s Construction and Design survey asks representatives from architecture, construction management, general contracting and development firms about the state of the healthcare construction industry over the past year and what they foresee for the sector. Here are five key takeaways from the survey. (Broderick and Davis, 5/3)

French vaccine maker Valneva (VLS.PA) reported on Thursday a smaller-than-expected first-quarter loss as sales of travel vaccines Dukoral and Ixiaro improved, propelling its shares 16% up. Valneva also confirmed its sales outlook for 2023, with revenue expected between 220 million euros and 260 million euros. (5/4)

Radiation therapy has been used to treat cancer for more than a century, and about half of all cancer patients still undergo it at some point, according to the National Cancer Institute. Typically, patients receive beams of radiation from a machine that kills cancer cells inside their bodies but can also damage healthy tissue. (Saltzman, 5/3)

Akili Interactive on Wednesday revealed earlier-than-expected top-line clinical trial results suggesting its video game treatment for attention deficit hyperactivity disorder is effective for adults. That’s very good news for a company that’s racing to reach more patients in hopes of building a sustainable business. (Aguilar, 5/3)

A drug approved in November as the first new treatment for advanced ovarian cancer in over seven years has now been shown to extend patients’ lives, its developer, Immunogen, said Wednesday. (Mast, 5/3)

The US Preventive Services Task Force (USPSTF) has published updated tuberculosis (TB) screening and treatment guidelines, including recommendations on testing at-risk adults for latent tuberculosis infection (LTBI). The recommendations were published yesterday in JAMA. The USPSTF updated its 2016 guidelines by commissioning a systematic review on LTBI screening and treatment in asymptomatic adults at primary care visits and on the accuracy of screening tests. (Van Beusekom, 5/3)

In other health care industry news —

A foundation that tried to block last year’s closure of Delaware County Memorial Hospital, part of Crozer Health, did not prove that the closure would cause irreparable harm to the community, a state appeals court ruled Wednesday. The Commonwealth Court ruling has no immediate impact, given that the Drexel Hill hospital’s emergency department and its inpatient units have been closed since the state Department of Health in early November ordered the facility to stop accepting patients because it lacked staff. (Brubaker, 5/3)

Patients seeking mental health treatment for themselves or their families too often find their insurers' provider directories riddled with inaccurate information, filled with names of providers who aren't accepting new patients or packed with contact information for providers who aren't actually accepting that form of insurance. (Raman, 5/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 1
  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF